Drug Profile
PAT LM1
Alternative Names: PAT-LM1Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Patrys
- Class Antibodies; Antineoplastics
- Mechanism of Action NONO protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in Australia (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Solid-tumours in Australia (Parenteral)
- 23 Apr 2014 PAT LM1 is available for licensing as of 23 Apr 2014. http://www.patrys.com/